fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

NHS to reimburse Kaftrio triple therapy to treat cystic fibrosis. – Vertex.

Written by | 4 Jul 2020 | Pharmacy

Vertex Pharmaceuticals Incorporated announced that it has expanded its reimbursement agreement with NHS England for Vertex’s cystic fibrosis medicines to include Kaftrio (ivacaftor/tezacaftor/elexacaftor), in a combination regimen with Kalydeco (ivacaftor) 150 mg, ahead of the medicine’s anticipated approval by the European Commission.

The new expanded agreement includes reimbursed access to Vertex’s currently licensed medicines — Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor), as well as the triple combination therapy if approved — and any future additional licensed indications for all of these medicines.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.